A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

Inclusion Criteria: * Patient is a primary liver transplant recipient * Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to transplant * Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures * Patient must receive 1st dose of study drug within 24 hours of pre-transplantation Exclusion Criteria: * Patient has previously received or is receiving an organ transplant other than a liver * Patient currently requires dialysis * Patient has received a liver transplant from a non-heart beating donor * Patient has received an ABO incompatible donor liver * Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) * Patient has fulminant hepatic failure, unless hemodynamically stable * Patient has an uncontrolled concomitant infection, a systemic infection requiring treatment (except viral hepatitis), or any other unstable medical condition that could interfere with the study objectives * Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant * Patient has a known hypersensitivity to tacrolimus, enteric-coated mycophenolate sodium or corticosteroids * Patient is pregnant or lactating